COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This study is a randomized, partially double-blind, three-arm, multicenter trial in HIV-infected subjects with long-term nucleoside exposure. Eligible subjects are participants in ACTG 302 or 303 who continue on their initially assigned nucleoside therapy. Subjects with plasma HIV RNA > 500 copies/ml, confirmed either at baseline or during their monitoring phase, will be randomized to (1) 2 RTIs + Nelfinavir (NFV), (2) 2 RTIs + DMP-266, or (3) 2 RTIs + NFV + DMP-266. The study will be partially blinded in that subjects will receive open-label reverse transcriptase inhibitors. The duration of study treatment is planned to be at least 48 weeks. Subjects with plasma HIV RNA < 500 copies/ml at baseline will continue to receive their current 302/303 nucleoside regimen, taken in an open-label capacity, as long as serial determinations of HIV RNA remain < 500 copies/ml. The cohort of subjects with delayed randomization will be analyzed separately; analysis of Part A subjects will not depend on completion of the study by the Part B subjects

Keywords: AIDS therapy; antiAIDS agent; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; reverse transcriptase inhibitors; virus RNA

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S3_0628 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950

OPEN LABEL TREATMENT OF HIV INFECTED SUBJECT WITH TIMUNOX

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This will be an open-label treatment study. Upon completion of the treatment regimen in an ongoing thermopentin U.S. clinical Phase 2 or 3 study, subjects will be offered the opportunity to enroll in this open- label study and will receive subcutaneous injections of thymopentin, 50 mg.1.0 mL, three times a week, every other day. Subjects currently enrolled in the ongoing open-label protocol (07.32.008-80) will be allowed to roll over into this study. Subjects will maintain their previously assigned study number and will continue to self-administer theri injections. Subjects whodiscontinue treatment with thymopentin for more than 1 month will not be allowed to restart thymopentin unless the investigator and the subject feel it is in the subjects best interest to do so. If a decision to restart thymopentin is make, complete written documentation of the rationale must be provided to the Sponsor by the Investigator prior to restarting treatment

Keywords: AIDS therapy; clinical research; dosage; drug administration rate /duration; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; thymopoietin

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0527 (1999): $0

NATURAL HISTORY OF RESISTANT MUCOSAL CANDIDIASIS IN AIDS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This wil be a prospective, observational substudy of ACTG 193/193A, ACTG 196 and ACTG 204 studying the natural history of resistant mucosal candidiasis in patients with HIV-1 Infection and low CD4+ lymphocyte counts

Keywords: candidiasis; clinical research; clinical trials; drug resistance; epidemiology; HIV infections; human subject; pathologic process

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0487 (1999): $0

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This study will enroll 10 people currently participating in the extension phase of ACTG 306 plus an additional 60 people not participating in ACTG 306. The study will last six months. The purpose of the study is 1) to compare the effects of two ZDV-containing drug combinations to see how many people have an undetectable viral load at both weeks 20 and 24; 2) to compare the safety of each of the three drug combinations

Keywords: AIDS; AIDS therapy; clinical research; clinical trials; combination chemotherapy; delavirdine; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; lamivudine; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S3_0630 (1999): $0

3M01RR000750-27S1_0630 (1999): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This study is a randomized, partially double-blind three, arm multicenter trial in HIV-infected subjects with long-term nucleoside exposure. Eligible subjects are participants in ACTG 302 or 303 who continue on their initially assigned nucleoside therapy. Subjects with plasma HIV RNA > 500 copies/ml, confirmed either at baseline or during their monitoring phase, will be randomized to (1) 2 RTIs + Nelfinavir (NFV), (2) 2 RTIs + DMP-266, or (3) 2 RTIs + NFV + DMP-266. The study will be partially blinded in that subjects will receive open- label reverse transcriptase inhibitors. The duration of study treatment is planned to be at least 48 weeks. Subjects with plasma HIV RNA < 500 copies/ml at baseline will continue to receive their current 302/303 nucleoside regimen, taken in an open-label capacity, as long as serial determinations of HIV RNA remain < 500 copies/ml. The cohort of subjects with delayed randomization will be analyzed separately; analysis of Part A subjects will not depend on completion of the study by the Part B subjects

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0628 (1999): $0

DELAVIRDINE MESYLATE IN COMBINATION WITH DIDANOSINE VS DDI ALONE IN HIV

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This protocol features a multicenter, multiple dose, randomized, double- blind design which will evaluate safety, tolerance, pharmacokinetics, antiviral and clinical efficacy. HIV-1 + males and females with a CD4 cell count of 0-300/mm3 will be treated with eaither DLV 400 mg TID plus ddL or with ddI alone

Keywords: 2`3` dideoxyinosine; AIDS therapy; clinical research; clinical trials; combination chemotherapy; delavirdine; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; leukocyte count; pharmacokinetics

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0463 (1999): $0

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a rollover protocol for patients previously enrolled in ACTG 320. Group A will involve a Phase II, randomized, double-blind, placebo- controlled study of 1592U89 in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) in NNRTI-naive and experienced subjects who have received (and are continuing to receive) ZDV (or d4T) + #TC + IDV and have plasma HIV-1 RNA concentrations <500 copies/ml at Screening. Group B will involve a Phase II, randomized, controlled evaluation of 1592U9 (vs. approved nucleoside analogs) and nelfinavir/NFV (vs. placebo) in combination with DMP-266 + adefovir dipivoxil inNNRTI-naive suvjects who have received ( and are continuing to receive) ZDV (or d4T) + 3TC + IDV and have plasma HIV-1 RNA concentrations > or = 500 copies/ml at Screening. Group C will involve a Phase II observational cohort of approximately 40 NNRTI-naive, ACTG 320 subjects with screening plasma HIV-1 RNA concentrations of 500-2000 copies/ml until approximately 16 weeks prior to the anticipated closure of Group B and followed until the closure of Group B

Keywords: AIDS therapy; antiAIDS agent; clinical research; combination chemotherapy; drug screening /evaluation; human immunodeficiency virus 1; human subject; human therapy evaluation; indinavir; lamivudine; placebos; protease inhibitor; reverse transcriptase inhibitors; stavudine; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0636 (1999): $0

3M01RR000750-27S3_0636 (1999): $0

INFLUENCE OF RISK FOR DISEASE PROGRESSION ON RESPONSE TO ANTIRETROVIRAL THERAPY

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a randomized, double-blind clinical trial involving subjects with prolonged prior experience with ZDV/ddI or ZDV/ddC combination therapies. Eligible subjects are participants in ACTG 175 who remanied of their initially assigned combination therapy until the end of follow-up in ACTG 175, or were crossed over to one of the combination therapies (because of a 50% deline for baseline in CD4+ cell count or the development of major HIV-related disease). They must also have remained on that combination therapy for any intervening period between the end of data collection for ACTG 175 (Feb 28,1995) and entry into ACTG 303. Subjects will be randomized to one of three treatment arms eith to continue their ZDV/ddI or ZDV/ddC, or to add 3TC to their ZDV/ddI or ZDV/ddC, or to switch to ZDV/3TC. The study will be partially blinded in that subjects will take either ddI or ddI placebo, or ddC or ddC placebo, as well as 3TC placebo. The primary outcome measure is change in HIV RNA copy number. The duration of study treatment is planned to be 48 weeks

Keywords: 2`3` dideoxyinosine; AIDS therapy; clinical research; clinical trials; combination therapy; disease /disorder proneness /risk; drug screening /evaluation; human subject; human therapy evaluation; lamivudine; outcomes research; pathologic process; reverse transcriptase inhibitors; virus RNA; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0529 (1999): $0

VIROLOGIC RESPONSE TO NUCLEOSIDE REGIMENS AFTER PROLONGED ZDV OR DDI MONOTHERAPY

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a randomized, double-blind clincal trial involving subjects with prolonged prior experience with ZDV of ddI monotherapy. Eligible subjects are participants in ACTG 175 whi remained on their initial assigned monotherapy until the end of follow-up in ACTG 175 (data collection closed of Feb.28,1995) and for any intervening period until entry into ACTG 302. This clinical trial comprises two sub-groups. One is for subjects who were assigned ZDV monotherapy in ACTG 175; these subjects will be randomized to receive eithe d4T monotherapy or the combination ot 3TC and ZDV, in a blinded manner. The other is for subjects who were assigned ddI monotherapy in ACTG 175; these subjects will be randomized to receive eithe the combination of ddI and ZDV or the combination of 3TC and ZDV, in a blinded manner. The primary outcome measure is change in HIV RNA copy number. The duration of study treatment is planned to be 48 weeks

Keywords: 2`3` dideoxyinosine; AIDS therapy; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; lamivudine; nucleoside analog; reverse transcriptase inhibitors; stavudine; virus RNA; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0530 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a randomized, double-blind 2-arm study designed to determine the antiviral activity and short term tolerability of didanosine dosed once or twice daily in HIV-infected subjects who have not received any antiretroviral treatment and who have plasma viral load of at least 10,000 HIV RNA copies/mL within 14 days prior to randomization

Keywords: 2`3` dideoxyinosine; AIDS therapy; antiAIDS agent; antiviral agents; clinical research; clinical trials; dosage; drug adverse effect; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; pharmacokinetics

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0620 (1999): $0

3M01RR000750-27S3_0620 (1999): $0

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a proposal for a screening clinic for patients referred to the Infectious Disease Research Clinic. They will be informed of clinical trials which may be available. If no trials are currently underway, a blood sample will be obtained and a history will be performed

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0289 (1999): $0

3M01RR000750-27S3_0289 (1999): $0

RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF INDINAVIR SULFATE (IDV)

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a Phase III randomized, double-blind study of IDV with open-label ZDV and 3TC with the option to switch from ZDV to open-label d4T for ZDV intolerance at anytime during the study or for disease progression short of a primary study endpoint after the first 24 weeks of therapy. A total of 1750 subjects with HIV infection who have CD4 cell counts <,= 200 cells/mm3 and >,= 6 months prior ZDV therapy will be included. Subjects will be randomly assigned to one of the following two treatments ARM 1 Open-label ZDV 200 mg TID + open-label 3TD 150 mg BID + IDV placebo TID (q8h) VERSUS ARM 2 Open-label ZDV 200 mg TID + open-label 3TC 150 mg BID + IDV 800 mg TID (q8h)

Keywords: AIDS therapy; clinical research; combination chemotherapy; HIV infections; human subject; human therapy evaluation; indinavir; lamivudine; leukocyte count; protease inhibitor; reverse transcriptase inhibitors; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0545 (1999): $0

ANTIVIRAL ACTIVITY AND RESISTANCE OF LAMIVUDINE IN COMBINATION WITH DDI OR D4T

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a Phase II, Randomized, Partially Double Blind, Six Arm Study. Subjects will be randomized twice at entry into the study. Initially, subjects will be randomized to either the ddI or d4T limbs and then within a limb, will be randomized a second time into one of three study arms. Randomiztion into one of the three study arms of each limb will occur in a 1.51.51 ratio. This randomization ratio is chosen in order to minimize sample size while retaining power to detect a 0.5-log10 difference between arms at Weeks 24 and 48. At study week 24, subjects on monotherapy will have lamivudine (3TC) added to their regimen in a blinded fashion. Subjects who begin the study on combination therapy will remain on that same combination therapy. To simplify dosing, blinding of limb assignment will not occur, but randomization into the arms of each of the limbs will be blinded

Keywords: 2`3` dideoxyinosine; AIDS therapy; antiviral agents; clinical research; combination chemotherapy; dosage; HIV infections; human subject; lamivudine; reverse transcriptase inhibitors; stavudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0533 (1999): $0

ISIS 2105 W/ VEHICLE CONTROL FOR SURGICAL ADJUNCTIVE THERAPY/CONDYLOM

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a multi-investigator, double-blind, randomized, vehicle-controlled, parallel study. The primary clinical diagnosis for patients who qualify for this study is condyloma acuminatum (genital warts)

Keywords: antisense nucleic acid; antiviral agents; clinical research; clinical trial phase I; condyloma acuminatum; drug screening /evaluation; drug vehicle; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; postoperative state

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S3_0643 (1999): $0

D4T VS ZDV PLUS D4T VS ZDV PLUS DDI IN HIV INFECTED PATIENTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a four-arm, randomzied, partially-blind, multicenter, Phase II study of nucleoside analogues given alone or in combination to subjects with CD4+ cell counts between 300-600/mm3 and greater that 24 weeks of ZDV experience. The four treatment arms are 1) d4T alone, 2) ddI alone, 3) ZDV and ddI in combination, 4) ZDV and d4T in combination. The administration of d4T and ddI will be open-label. The study is double- blind with respect to ZDV treatment. The duration of the study is 48 weeks after the enrollment of the last subject. A 12 week blinded study extension wil be offered to all subjects still on blinded therapy upon the conclusion of the original 48 weeks after the last subject is enrolled

Keywords: 2`3` dideoxyinosine; AIDS therapy; antiviral agents; clinical research; combination chemotherapy; HIV infections; human subject; human therapy evaluation; stavudine; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0509 (1999): $0

DELAVIRDINE MESYLATE IN COMBINATION WITH ZIDOVUDINE VS ZDV ALONE IN HIV

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: Multiple-dose, randomized, double-blind study of oral delavirdine mesylate doses of 200, 300, or 400 mg three times daily (TID), in combination with standard dose of ZDV therapy vs ZDV therapy alone

Keywords: AIDS therapy; clinical research; clinical trials; combination chemotherapy; delavirdine; dosage; HIV infections; human subject; human therapy evaluation; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0462 (1999): $0

ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: In this phase III trial, HIV-infected women diagnosed with CIN I by cervical biopsy will be randomized to either oral isotretinoin or observation for 6 months. Randomized subjects on both arms will be followed to the study termination to assess persistence/recurrence or progression of CIN I. Subjects who reach an endpoint of CIN II or III that is confirmed by a biopsy by central pathology review may be eligible for protocol ACTG 200 or they may be followed by their personal gynecologist. The primary objective To determine the efficacy of oral isotretinoin for prevention of progression of mild dysplasia to more severe dysplasia by comparing the time to progression of CIN I to CIN II, III, or invasive cancer in subjects receiving isotretinoin vs. observation. The secondary objectives To determine the efficacy of oral isotretinoin for the treatment of CIN I by comparing the proportion of subjects who are free of dysplasia at 6 months among those receiving isotretinoin vs observation; and to assess the adverse effects and toxicity or oral isotretinoin in HIV-infected women. Tertiary objectives To correlate baseline CD4+ and CD8+ cell counts with time to progression to CIN II, III, or invasive cancer. To document potential differences between progression and/or regression of subjects who are being treated for primary vs recurrent dysplasia

Keywords: 13 cis retinoate; AIDS therapy; cancer prevention; cervix neoplasms; chemoprevention; clinical research; drug screening /evaluation; female; HIV infections; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer remission /regression; neoplastic growth; oral administration; uterus preneoplastic state; women`s health

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S3_0645 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500

ZDV VS DDI VS ZDV PLUS DDI PLUS NEVIRAPINE IN ASYMPTOMATIC HIV PATIENTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: A Double-Blinded, Randomized Trial Comparing Zidovudine (ZDV) vs ZDV + Didanosine (ddI) vs ZDV + ddI + Nevirapine in Asymptomatic Patients on ZDV monotherapy who develop a mutation at codom 215 of HIV reverse transcriptase in serum/plasma viral RNA (ACTG 244)

Keywords: 2`3` dideoxyinosine; AIDS therapy; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; nevirapine; virus genetics; zidovudine

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0476 (1999): $0

ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0645 (2000): $0

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0289 (2000): $0

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0636 (2000): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0628 (2000): $0

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0630 (2000): $0

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S2_0620 (2000): $0

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0636 (2000): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0628 (2000): $0

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0630 (2000): $0

Sponsored Links Excellgen http://Excellgen.com

	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0620 (2000): $0

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0289 (2000): $0

ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S3_0645 (2000): $0

3M01RR000750-28S4_0645 (2000): $0

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S4_0289 (2000): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S4_0628 (2000): $0

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S4_0630 (2000): $0

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S4_0620 (2000): $0

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S4_0636 (2000): $0

ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0645 (2000): $0

Sponsored Links Excellgen http://Excellgen.com

	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0289 (2000): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0628 (2000): $0

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0630 (2000): $0

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0620 (2000): $0

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

3M01RR000750-28S5_0636 (2000): $0

NUCLEOSIDE THERAPY FOR ADVANCED HIV DISEASE WITH PRIOR NUCLEOSIDE THERAPY

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

3M01RR000750-27S1_0396 (1999): $0

Grants awarded to H Kenneth

TUBULIN STRUCTURE BY ELECTRON CRYSTALLOGRAPHY

H Kenneth
University Of Calif-lawrenc Berkeley Labcity: Berkeley country: United States (us)

Abstract: We will study the molecular structure of tubulin in crystalline sheets which are induced by small concentrations of zinc ions. Structural information obtained should help in understanding the ways in which tubulin in microtubules and other assemblies carries out its myriad of functions during the development and life of a cell. Electron crystallography, which is ideally suited to the study of twodimensional specimens such as these sheets, will be the main experimental technique. Data from electron micrographs of the crystalline lattice and, where possible, electron diffraction patterns can be combined to yield a three-dimensional density map of the molecule, and this map can then be interpreted in terms of the atomic structure. Electron crystallographic techniques have developed over the last few years to the point where we can make significant contributions using the types of tubulin sheets which have been used in previously published structural studies. We will, though, spend some effort on improving the size and quality of these sheets in order to make extension of this work to high resolution simpler and more efficient

Keywords: animal tissue; circular dichroism; crystallization; electron density; electron microscopy; polymerization; protein purification; protein structure function; tubulin; zinc

Project start date: 1992-08-01

Project end date: 1996-07-31

Budget start date: 1-AUG-1995

Budget end date: 31-JUL-1996

5R01GM046033-04 (1995): $0

5R01GM046033-03 (1994): $0

5R01GM046033-02 (1993): $0

1R01GM046033-01A1 (1992): $0

BILIVERDIN IN MELANOMA CELL DIFFERENTIATION

H Kenneth
Brigham And Women´s Hospitalcity: Boston country: United States (us)

Abstract: We reported that biliverdin is required for formation of eyes, brain, spinal cord and other dorsal organs in amphibia. Beyond that mandatory requirement for embryogenesis, we found that biliverdin is a pleiotropic molecule capable of altering the phenotypes of a number of cancer cells to a more differentiated state. An early and common behavior caused by biliverdin is an arrest of proliferation in six cancer cells (melanoma, colon adenocarcinoma, liposarcoma, thyroid carcinoma, T and B cell lymphomas). In colon adenocarcinoma, the c Myc oncogene disapp9ears within two days of incubating with 5 x 10-7 M biliverdin. Concurrently, biliverdin slows their G1 to S transition. Subsequently, two differentiation markers, CEA and alkaline phosphatase, are up-regulated. These findings suggest that biliverdin reverses the phenotypic consequences of APC and beta catenin mutations characteristic of colon adenocarcinoma. Central to the current proposal are the documented findings that, like in colon adenocarcinoma, melanoma cells characteristically exhibit mutations in the same signaling system including GSK3beta phosphorylation sites of beta catenin and/or abnormally expressing high amounts of beta catenin itself. These mutations and over-expression lead to an increase in stable cytoplasmic beta catenin and enhanced transcription of beta catenin/Tef/Lef oncogenes, such as c Myc. The common alterations in beta catenin signaling found in colon cancer and melanoma cells calls for examination of the possibility that the dermatological malignancy also may be responsive to the effects of biliverdin and be directed along a differentiation pathway. In favor of this premise is a) our finding that biliverdin arrests cell division if SJ NEK 24 melanoma cell and b) literature reports that 12-o-tetra decanoyl phorbol 13 acetate (TPA), a molecule that up-regulates heme oxygenase 1 (HO 1) in cancer cells and, therefore, must lead to an increase in biliverdin content of these cells, also inhibits proliferation of melanoma cells. Consequently, we propose to examine the effect of biliverdin on SK MEL 24 phenotype focusing on oncogene molecules transcriptionally regulated by the beta catenin signaling system (Aim 1) and on beta catenin itself and GSK3beta, the enzyme responsible for its phosphorylation and degradation (Aim 2). These two aims will be examined by incubating the SK MEL 24 cells with biliverdin. If the results are positive, we will examined these same molecules in SK MEL 24 cells induced to synthesize biliverdin in response to phenylarsine oxide, a known activator of heme oxygenase 1 (Aim 3). Positive results will demonstrate that melanoma cells can be made to undergo differentiation and open the door to possible novel therapeutic interventions

Keywords: bile pigments; cadherins; calmodulin dependent protein kinase; carcinogenesis inhibitor; cell differentiation; cell line; melanoma; northern blottings; oncogenes; western blottings

Project start date: 2002-04-01

Project end date: 2004-03-31

5P30AR042689-09_0041 (2002): $0

DRUG EFFECTS ON AUTOMATICITY IN THE HEART

H Kenneth, Assistant Professor Of Medicin
Columbia Univ New York Morningsidecity: New York country: United States (us)

Abstract: We propose to use standard microelectrode techniques to study the electrophysiology and pharmacology of spontaneous impulse initiation in partially depolarized canine Purkinje fibers and myocardium. Abnormal automaticity will be induced in isolated Purkinje fibers and ventricular muscle preparations by current clamp depolarization techniques, or by depolarization with barium chloride, cesium chloride or palmityl carnitine. Triggered activity from early afterdepolarizations will be induced in Purkinje fibers with N-acetyl procainamide or cibenzoline. The response of both types of abnormal impulses will be studied with standard stimulation protocols, including intracellular current pulses, and will be compared to the results obtained from analogous studies on automaticity in normal Purkinje fibers. We will study the effects of standard and experimental antiarrhythmic drugs on these experimental models of abnormal automaticity. We will carry out parallel studies on the effects of these drugs on similar types of abnormal automaticity that occur in pathological canine (15-30 hr infarct zone Purkinje fiber) or feline cardiac tissues. Drug studies will also be carried out on triggered activity in infarct zone preparations when this is encountered. We will try to develop a model of "current of injury" induced abnormal automaticity, as may occur during acute ischemia. These studies should give us insights into the electrophysiological mechanisms of cardiac arrhythmias, and may lead to improved, and perhaps rational, pharmacotherapy. If possible, we will extend extracellular unipolar recording techniques to detect electrical activity from the endocardial surface of the in situ canine ventricle 1. to detect early afterdepolarizations and triggered activity in hearts made arrhythmic with N-acetyl procainamide, and 2. to detect activity during VPDs during the 24-hour arrhythmias occurring after coronary ligation, to demonstrate the presence of abnormal automaticity or triggered (EAD or DAD) activity

Keywords: antiarrhythmic agent; barium; cardiotonic agents; carnitine; depolarizing neuromuscular blocking agent; disease /disorder model; drug metabolism; electrophysiology; heart conduction system; heart contraction; heart disorder chemotherapy; heart pharmacology; heart Purkinje`s fiber; ischemia; lidocaine; membrane potentials; microelectrodes; myocardium; phenothiazines; procainamide; propranolol; verapamil

Project start date: 1979-08-01

Project end date: 1989-07-31

Budget start date: 1-AUG-1987

Budget end date: 31-JUL-1989

5R01HL024354-09 (1987): $0

OPEN LABEL TREATMENT OF HIV INFECTED SUBJECT WITH TIMUNOX

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS therapy; clinical research; dosage; drug administration rate /duration; drug screening /evaluation; HIV infections; human subject; human therapy evaluation; thymopoietin

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0527 (1999): $0

5M01RR000750-26_0527 (1998): $0

NATURAL HISTORY OF RESISTANT MUCOSAL CANDIDIASIS IN AIDS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: candidiasis; clinical research; clinical trials; drug resistance; epidemiology; HIV infections; human subject; pathologic process

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0487 (1999): $0

5M01RR000750-26_0487 (1998): $0

Sponsored Links Excellgen http://Excellgen.com

	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950

THE ROLE OF THE PULVINAR IN VISUAL ATTENTION

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Abstract: This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective The pulvinar nucleus of the thalamus is one of the most enigmatic structures in the brain. Of thalamic nuclei, it shows the largest increase in size with evolution, keeping pace with the size of primate neocortex. Despite considerable effort, its function remains essentially completely unknown. Two related suggestions dominate current thinking about the pulvinar, and each has some experimental support. Neither, however, has been critically tested, and the present application is intended to provide this critical test of both ideas. The first idea is that the pulvinar controls the spatial location of directed attention. This idea has support - though not conclusive - from lesion studies and physiological recording studies. We plan to directly test this idea by perturbing activity in the pulvinar while recording in extrastriate cortex. We know that directed attention produces local changes in the gain of response of extrastriate neurons; activation of the pulvinar should mimic this change and reversible inactivation of the pulvinar should eliminate it. The other suggestion for the role of the pulvinar concerns the mechanism of such gain changes in sensory cortex. In particular, it has been suggested that recurrent projections between the pulvinar and cortical structures control the flow of information between cortical areas; this regulation might underlie any role in directing spatial attention. We plan to test this idea using multiple electrode recording in extrastriate cortex. Two dorsal extrastriate areas, the middle temporal (MT) and the medial superior temporal (MST) are both connected to the same subdivision of the pulvinar (Plm), and also connected with each other - MT provides a dominant source of feedforward input to MST. We will record from both structures simultaneously while again perturbing the activity in the pulvinar. If the connections with the pulvinar regulate information flow in visual cortex, we predict that such perturbation will modulate the cross-correlation of activity between MT and MST. Success on either aim will dramatically influence our thinking about the function of thalamocortical circuits

Keywords: Area; Attention; Brain; Cell Nucleus; Computer Retrieval of Information on Scientific Projects Database; directed attention; Dorsal; Electrodes; Evolution; extrastriate; extrastriate visual cortex; Funding; Grant; Institution; Lesion; Location; Medial; Neocortex; Neurons; Physiological; Primates; Pulvinar structure; Recurrence; Regulation; Research; Research Personnel; Resources; response; Role; sensory cortex; size; Source; Structure; success; Suggestion; Testing; Thalamic Nuclei; Thalamic structure; Thinking, function; United States National Institutes of Health; Visual attention; Visual Cortex

Project start date: 2008-05-01

Project end date: 2009-04-30

Budget start date: 1-MAY-2008

Budget end date: 30-APR-2009

5P51RR000169-47_5768 (2008): $27111

HEIRARCHICAL PROCESSING IN THE MOTION SYSTEM

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Abstract: This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective The basic "building blocks" of visual perception are starting to become reasonably well understood, and we can make a fairly good account of how simple discriminations are done. What we understand much less is how the visual system solves more realistic, everyday challenges. Visually guided navigation is a particularly good "model system" for studying real-world visual processes in the laboratory. The perception of self-motion from the pattern of motion on the retina has been studied extensively, though we still know very little about where in the brain the critical processing steps occur, and how the complex pattern of motion is converted into effective movement. The present proposal seeks to answer these open questions. First, we will seek direct evidence for the involvement of multiple cortical areas in the perception of self-motion, by using multiple, simultaneous recording techniques while our experimental animals are performing a discrimination of self-motion direction. Secondly, we will seek to ask if the parietal cortical area (the ventral intraparietal area or VIP) is both necessary for self-motion perception and is actually used. We will do this by perturbing the pattern of activity in VIP in the context of the self-motion task, both by reversible inactivation as well as by electrical activation. These complementary methods should greatly extend our understanding of how the parietal cortex participates in self-motion perception. However, to really extend our knowledge of self-motion perception, we need to extend the inquiry into a more active context. Human-factors studies have revealed that guidance of self-motion ("steering") is a very active process, with the direction of gaze being a critical component. However, next to nothing is known about the central nervous system mechanisms used in this active task. So, we propose to establish, characterize and exploit an animal model of active locomotion to study the involvement of brain structures in this task. We will train our subject to direct their "virtual" trajectories by joystick, and characterize how their normal behavior is influenced by cues including target direction, gaze direction, gaze velocity, and visual motion information. We will then record activity in multiple cortical areas while animals are engaged in this task, and explore the signals in visual and parietal cortex to better understand brain mechanisms of visually guided navigation. This information, in the long term, might be useful in helping the disabled to navigate, and in the development of visual prosthetics for the blind

Keywords: Accounting; Animal Model; Animals; Area; Behavior; Biological Models; blind; Brain; Complex; Computer Retrieval of Information on Scientific Projects Database; Cues; Disabled Persons; Discrimination (Psychology); Funding; gaze; Grant; Human; Institution; Joystick; Laboratories; Locomotion; Methods; Motion; Motion Perception; Movement; Neuraxis; Parietal; Parietal Lobe; Pattern; Process; Prosthesis; Research; Research Personnel; Resources; Retina; Self Perception; Signal Transduction; Source; Structure; System; Techniques; Training; United States National Institutes of Health; ventral intraparietal area; virtual; vision development; Visual; Visual Motion; Visual Perception; visual process; visual processing; Visual system structure

Project start date: 2008-05-01

Project end date: 2009-04-30

Budget start date: 1-MAY-2008

Budget end date: 30-APR-2009

5P51RR000169-47_5739 (2008): $27111

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: Blood specimen; Clinic; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Evaluation; Funding; Grant; Infectious Diseases Research; Institution; Participant; Patients; Recording of previous events; Research; Research Personnel; Resources; Screening procedure; Source; United States National Institutes of Health

Project start date: 2007-12-01

Project end date: 2008-05-31

Budget start date: 1-DEC-2007

Budget end date: 31-MAY-2008

5M01RR000750-36_7577 (2008): $69967

A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: Age; antiretroviral therapy; Clinical; Computer Retrieval of Information on Scientific Projects Database; Contraceptive Agents; Count; Dose; Drug Kinetics; Enrollment; Ethinyl Estradiol; Funding; Grant; HIV-1; Institution; Label; Laboratories; Lopinavir/Ritonavir; Measures; Menstrual fluid; Menstruation; Monitor; non-nucleoside reverse transcriptase inhibitors; norelgestromin; Oral Contraceptives; Ortho Evra; Ortho-Novum; Phase; Plasma; Protease Inhibitor; Questionnaires; Randomized; reproductive; Research; Research Personnel; Resources; Source; System; Telephone; Testing; Treatment Protocols; United States National Institutes of Health; Visit; Week; Woman

Project start date: 2007-12-01

Project end date: 2008-05-31

Budget start date: 1-DEC-2007

Budget end date: 31-MAY-2008

5M01RR000750-36_7641 (2008): $4543

HEIRARCHICAL PROCESSING IN THE MOTION SYSTEM

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Keywords: Area; area MT; base; Computer Retrieval of Information on Scientific Projects Database; Cues; Funding; Grant; Institution; interest; Investigation; Motion; Parietal Lobe; Process; Research; Research Personnel; Resources; Source; System; United States National Institutes of Health; ventral intraparietal area; Visual

Project start date: 2007-05-01

Project end date: 2008-04-30

Budget start date: 1-MAY-2007

Budget end date: 30-APR-2008

5P51RR000169-46_7054 (2007): $24607

THE ROLE OF THE PULVINAR IN VISUAL ATTENTION

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Project start date: 2007-05-01

Project end date: 2008-04-30

Budget start date: 1-MAY-2007

Budget end date: 30-APR-2008

5P51RR000169-46_7090 (2007): $57422

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 2006-12-01

Project end date: 2007-11-30

Budget start date: 1-DEC-2006

Budget end date: 30-NOV-2007

5M01RR000750-35_8270 (2007): $293476

A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 2006-12-01

Project end date: 2007-11-30

Budget start date: 1-DEC-2006

Budget end date: 30-NOV-2007

5M01RR000750-35_8334 (2007): $19057

HEIRARCHICAL PROCESSING IN THE MOTION SYSTEM

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Project start date: 2006-05-01

Project end date: 2007-04-30

Budget start date: 1-MAY-2006

Budget end date: 30-APR-2007

5P51RR000169-45_5768 (2006): $24804

THE ROLE OF THE PULVINAR IN VISUAL ATTENTION

H Kenneth, Professor
University Of California Daviscity: Davis country: United States (us)

Project start date: 2006-05-01

Project end date: 2007-04-30

Budget start date: 1-MAY-2006

Budget end date: 30-APR-2007

5P51RR000169-45_5826 (2006): $49710

Sponsored Links Excellgen http://Excellgen.com

	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 2005-12-01

Project end date: 2006-11-30

Budget start date: 1-DEC-2005

Budget end date: 30-NOV-2006

5M01RR000750-34_5145 (2006): $216369

PREVALENCE OF HPV DNA IN HIV INFECTED WOMEN WHO HAVE INITIATED HAART (A5029)

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 2005-12-01

Project end date: 2006-11-30

Budget start date: 1-DEC-2005

Budget end date: 30-NOV-2006

5M01RR000750-34_5164 (2006): $2193

A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 2005-12-01

Project end date: 2006-11-30

Budget start date: 1-DEC-2005

Budget end date: 30-NOV-2006

5M01RR000750-34_5235 (2006): $1463

VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

2M01RR000750-28_0630 (2000): $0

5M01RR000750-27_0630 (1999): $0

5M01RR000750-26_0630 (1998): $0

COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This study is a randomized, partially double-blind, three-arm, multi-center trial in HIV-infected subjects with long-term nucleoside exposure. Eligible subjects are participants in ACTG 302 or 303 who continue on their initially assigned nucleoside therapy. Subjects with plasma HIV RNA > 500 copies/ml, confirmed either at baseline or during their monitoring phase, will be randomized to (1) 2 RTIs + Nelfinavir (NFV), (2) 2 RTIs + DMP-266, or (3) 2 RTIs + NFV + DMP-266. The study will be partially blinded in that subjects will receive open-label reverse transcriptase inhibitors. The duration of study treatment is planned to be at least 48 weeks. Subjects with plasma HIV RNA < 500 copies/ml at baseline will continue to receive their current 302/303 nucleoside regimen, taken in an open-label capacity, as long as serial determinations of HIV RNA remain < 500 copies/ml. The cohort of subjects with delayed randomization will be analyzed separately; analysis of Part A subjects will not depend on completion of the study by the Part B subjects

Project start date: 1999-12-01

Project end date: 2000-11-30

2M01RR000750-28_0628 (2000): $0

5M01RR000750-27_0628 (1999): $0

5M01RR000750-26_0628 (1998): $0

DELAVIRDINE MESYLATE IN COMBINATION WITH DIDANOSINE VS DDI ALONE IN HIV

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0463 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950

5M01RR000750-26_0463 (1998): $0

GORDON RESEACH CONFERENCE ON 3D EM OF MACROMOLECULES

H Kenneth
Gordon Research Conferencescity: West Kingston country: United States (us)

Grant 5R13RR018366-03 from National Center For Research Resources

Abstract: This proposal requests support for the 10th Gordon Research Conference (GRC) on 3D Electron Microscopy of Macromolecules. EM occupies a unique position in the biological armamentarium in that it can address questions at the molecular and cellular level that are unapproachable by other structural methods. EM can bridge light microscopic studies at subcellular resolutions with atomic resolution structures provided by X-ray crystallography and NMR. Recent, technical breakthroughs enable 3D structures to be determined with ever-increasing accuracy thereby opening the way to the study of macromolecular systems under defined physiological conditions. The result is new opportunities for understanding biological mechanisms, interactions between macromolecules and the principles of bimolecular design. This series of conferences fosters an integrated view of biological complexity by bringing together scientists working at different levels of the structural hierarchy. These meetings serve to define the challenges of the future and to focus a concerted approach to problems in the preparation, imaging and interpretation of biological specimens that range in size from the molecular to the subcellular. The impact of the preceding nine conferences has been such that the 3D EM community has come to regard this GRC as an event of pivotal importance. The 2003 conference is organized around the theme of "Bridging Cellular, Molecular and Atomic Resolution". Our goal has been to create a dynamic forum for (i) the dissemination of major progress in the field over the past two years and (ii) identification of new technical and biological challenges, which must be addressed in order for 3D EM to become an essential and ubiquitous tool for solving cell biological problems. In the spirit of the GRC, we have chosen a program that represents the frontier of our field. Speakers have been chosen based on the importance of their recent contributions and the potential impact of their particular research approach. Speakers from outside the field have been selected in the hope of fostering interdisciplinary approaches and for challenging the field to reach in directions it has so far not contemplated. Based on past experience, we confidently expect that the 3D EM GRC will continue to play a central role in defining new technical challenges, and in focusing a concerted approach to understanding fundamental biological questions

Keywords: electron microscopy; macromolecule; meeting /conference /symposium; travel

Project start date: 2003-04-01

Project end date: 2008-03-31

Budget start date: 1-APR-2005

Budget end date: 31-MAR-2006

5R13RR018366-03 (2005): $6650

OCCUPATIONAL SAFETY AND HEALTH TRAINING PROGRAM CONTINU*

H Kenneth
Oregon State Universitycity: Corvallis country: United States (us)

Grant 1T01OH008407-01 from National Institute For Occupational Safety And Health

Abstract: This proposal is to establish a coordinated graduate degree program in occupational safety and health within the Departments of Industrial and Manufacturing Engineering (IME) and Public Health (PH) at Oregon State University (OSU). The programs were previously separate. This was funded for the first time in 2002 (for 3 years), with Woldstad as the PI, who has since left the University. It is not clear when the graduate programs started. Separately administered academic programs will lead to a Masters of Science (M.S.) degree in Industrial and Manufacturing Engineering with an emphasis in human systems engineering, or an M.S. degree in Environment, Safety and Health with an emphasis in occupational safety. The purpose of the training program is to provide students with a sound educational experience in occupational safety and health, including academic coursework, practical experience and research. The program is designed to prepare students for careers as occupational safety and health, human factors, and ergonomic specialists in both private and governmental sectors. The core curriculum for this program consists of 5 quarter courses in (PH) focusing on occupational safety and health including, industrial hygiene, and 5 quarter courses in (IME) focusing on ergonomics and human factors engineering. There are still two separately administered programs, but they are now coordinating coursework. The program is designed to be completed in approximately 18 months. IME courses focus on ergonomics, with the PH courses focused on safety and IH. They require 49-53 credits for IME and 48 for the PH (trimester system)

Project start date: 2005-07-01

Project end date: 2006-06-30

Budget start date: 1-JUL-2005

Budget end date: 30-JUN-2006

PFA/PA: RFA-OH-05-001

1T01OH008407-01 (2005): $22909

BIOMARKERS OF EXPOSURE AND RESPONSE TO ENVIRONMENTAL TOBACCO SMOKE IN THE PANCREA

H Kenneth
Sloan-kettering Institute For Cancer Rescity: New York country: United States (us)

Grant 1K08ES019615-01 from National Institute Of Environmental Health Sciences

Abstract: This proposal describes a systems biology approach to biomarker discovery and validation focused on exposure to environmental tobacco smoke (ETS) and its causal link to pancreatic ductal adenocarcinoma (PDAC). Cigarette smoke (CS) is an extremely complex mixture, including numerous tobacco-specific nitrosamines (TSNAs). The present proposal stems from significant advances the investigators have made in the quantification of tobacco-derived compounds and protein biomarkers using stable isotope methodology. CS is the major known environmental risk factor for PDAC, with recent studies implicating both mainstream tobacco smoke and ETS. PDAC is the 4th most common cause of cancer-related mortality in the US and is universally lethal. This research plan is based on four important observations 1) TSNA metabolism varies greatly among individuals, and higher levels have been associated with lung cancer. 2) TSNAs have also been shown to cause PDAC in laboratory animals. 3) ETS, which contains TSNAs, causes pancreatic inflammation in exposed rats. 4) Pancreatic inflammation and PDAC result in specific changes in proteins secreted by pancreatic cells which we have extensively characterized. Based on these observations, the investigators have developed the following hypotheses ETS exposes the pancreas to toxic chemicals exemplified by NNK and its metabolite NNAL. Inter-individual differences in metabolism cause serum and tissue levels of these toxic chemicals to vary widely, contributing to differences in PDAC susceptibility. Exposure of the pancreas to these toxic chemicals results in inflammation and secretion of biomarkers that can be quantified and used to asses an individual´s risk for PDAC. To test these hypotheses, the following objectives/specific aims will be pursued 1) To use an in vitro system to characterize and quantify proteomic and metabolomic biomarkers of pancreatic ETS exposure and biological response. 2) To develop panels of biomarkers using stable isotope labeling methodology in order to rigorously assess pancreatic ETS exposure and biological response. 3) To use serum and urine samples from PDAC subjects with quantified levels of ETS exposure and non-exposed controls to refine a biomarker panel of ETS exposure and biological response identified in aim 2. 4) To perform a replication study of the biomarker panel developed in aim 3 to assess the sensitivity and specificity of an individual´s risk for PDAC. This proposal will elaborate on the innovative methods developed and significant findings already made by the principal investigator. A unique, interdisciplinary approach has been developed to execute the research described. By achieving these specific aims, this proposal will have a highly significant impact on the field. Furthermore, the investigators´ results will shed important light on the etiological role of ETS in PDAC. Biomarkers developed will be used for identifying persons at increased risk for and with early stage PDAC. This translational approach will impact on clinical practice by offering the possibility of surgical resection, which is currently the only realistic option for improving survival from this devastating disease

Keywords: 1-Butanol; Abscission; Advisory Committees; Aromatic Polycyclic Hydrocarbons; Asses; base; Bio-Informatics; Bioinformatics; Biological; biomarker; Biometrics; Biometry; Biometry and Biostatistics; Biostatistics; Blood Serum; Body Tissues; Butas; Cancer Cause; Cancer Etiology; Cancer of Lung; cell biology; Cells; Cellular biology; cigarette smoke; Clinical; clinical practice; Collaborations; Common Rat Strains; Complex Mixtures; Development; Diagnosis; Disease; disease/disorder; Disorder; Doctor of Medicine; Doctor of Philosophy; Donkey; Early treatment; Educational Mainstreaming; Ensure; Environmental Factor; environmental risk; Environmental Risk Factor; Environmental Tobacco Smoke; environmental tobacco smoke exposure; Enzyme Activation; Equus asinus; Excision; experience; Exposure to; Extirpation; Gastrointestinal Tract, Pancreas; gene product; improved; In Vitro; Individual; Individual Differences; Inflammation; INFLM; innovate; innovation; innovative; interdisciplinary approach; Intermediary Metabolism; Investigators; Laboratories; Laboratory Animals; language translation; Light; Link; lung cancer; M.D.; Mainstream Education, achievement; Mainstreaming; Mainstreaming (Education); Malignant neoplasm of lung; Malignant Tumor of the Lung; Mammals, Rats; Mass Spectrum; Mass Spectrum Analysis; measurement of metabolism; Medicine; member; Mentors; Metabolic Processes; Metabolism; metabolomics; METBL; Method LOINC Axis 6; Methodology; Methods; Modeling; Mortality; Mortality Vital Statistics; n-Butanol; n-Butyl Alcohol; National Institute of Environmental Health Sciences; Nitrosamine Metabolism; Nitrosamines; Operation; Operative Procedures; Operative Surgical Procedures; Oxidative Stress; PAH; Pancreas; Pancreas Ductal Adenocarcinoma; Pancreatic; Pancreatic Ductal Adenocarcinoma; Pathologist; Pathology; Persons; Ph.D.; PhD; Photometry/Spectrum Analysis, Mass; Photoradiation; poison; Poisons; Polycyclic Hydrocarbons, Aromatic; polynuclear aromatic hydrocarbon; Polynuclear Aromatic Hydrocarbons; Predisposition; Principal Investigator; professor; programs; Programs (PT); Programs [Publication Type]; Proteins; Proteomics; Pulmonary Cancer; Pulmonary malignant Neoplasm; Rat; Rattus; Removal; Research; Research Design; Research Personnel; Research Resources; Researchers; resection; Resources; response; Risk; Role; Sampling; Science of Medicine; Scientist; second hand smoke; Sensitivity and Specificity; Serum; Smoke; smoke of cigarettes; social role; Spectrometry, Mass; Spectroscopy, Mass; Spectrum Analyses, Mass; Spectrum Analysis, Mass; stable isotope; Stable Isotope Labeling; Staging; statistics/biometry; stellate cell; stem; study design; Study Type; surgery; Surgical; Surgical Interventions; Surgical Procedure; Surgical Removal; Survival Rate; Susceptibility; System; System, LOINC Axis 4; Systems Biology; Task Forces; Testing; Tissue Stains; Tissues; Tobacco; Tobacco smoke; Toxic Chemical; toxic compound; Toxic Substance; Translating; Translatings; translational approach; Urinary System, Urine; Urine; Validation

Relevance: Narrative: The systems biology approach presented in this proposal will develop environmental tobacco smoke (ETS) and pancreas derived biomarkers of exposure and response. These studies will inform the etiological link between ETS and pancreatic ductal adenocarcinoma (PDAC), leading to improved clinical practice. We envision a fruitful line of study, with results generated from this proposal forming the basis for an independent research program

Project start date: 2011-01-01

Project end date: 2013-12-31

Budget start date: 1-JAN-2011

Budget end date: 31-DEC-2011

PFA/PA: PA-10-059

1K08ES019615-01 (2011): $180684

ELECTRON MICROSCOPY OF BIOLOGICAL MACROMOLECULES

H Kenneth
University Of Calif-lawrenc Berkeley Labcity: Berkeley country: United States (us)

Grant 5P01GM051487-16 from National Institute Of General Medical Sciences

Abstract: This Program Project represents a coordinated and mutually supporting effort to pursue research in structural biology where electron diffraction and electron microscopy play a key role and to advance the technology that enables this research. Three projects within the Program represent applications of the methods of electron crystallography and microscopy, as well as of the instrumentation supported by the Program, to specific problems in structural biology. These applications focus on aspects of the eukaryotic cytoskeleton and include (Project A) Studies of the structure of tubulin and its interactions with ligands and other proteins that affect the function of the microtubule cytoskeleton; (Project B) Studies of the apparatus in the inner ear that converts sound to nerve signals and controls sensitivity of hearing; (Project C) Studies of the proteins that connect microtubules to chromosomes and ensure proper chromosome segregation during cell division. Additional, separately funded research projects which rely to a smaller extent on equipment and facilities supported by the Program Project are also included as Associate member projects. The Administrative Core (Project D) maintains the major equipment, supports computer resources, continues our efforts to improve the quality and throughput of electron microscopy data, and provides a sense of intellectual community and common identity for all the participants in the Program Project. Our structural studies of several medically important protein complexes that play essential roles within the cell provide the basis for understanding their normal function as well as failures in these functions that are associated with disease and birth defects

Project start date: 1997-07-01

Project end date: 2015-05-31

Budget start date: 1-JUN-2011

Budget end date: 31-MAY-2012

PFA/PA: PA-07-030

5P01GM051487-16 (2011): $1816425

2P01GM051487-15 (2010): $1830535

PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Abstract: This is a rollover protocol for patients previously enrolled in ACTG 320. Group A will involve a Phase II, randomized, double-blind, placebo-controlled study of 1592U89 in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) in NNRTI-naive and experienced subjects who have received (and are continuing to receive) ZDV (or d4T) + TC + IDV and have plasma HIV-1 RNA concentrations <500 copies/ml at screening. Group B will involve a Phase II, randomized, controlled evaluation of 1592U9 (vs. approved nucleoside analogs) and nelfinavir/NFV (vs. placebo) in combination with DMP-266 + adefovir dipivoxil in NNRTI-naive subjects who have received (and are continuing to receive) ZDV (or d4T) + 3TC + IDV and have plasma HIV-1 RNA concentrations > or = 500 copies/ml at Screening. Group C will involve a Phase II observational cohort of approximately 40 NNRTI-naive, ACTG 320 subjects with screening plasma HIV-1 RNA concentrations of 500-2000 copies/ml until approximately 16 weeks prior to the anticipated closure of Group B and followed until the closure of Group B

Project start date: 1999-12-01

Project end date: 2000-11-30

2M01RR000750-28_0636 (2000): $0

5M01RR000750-27_0636 (1999): $0

5M01RR000750-26_0636 (1998): $0

INFLUENCE OF RISK FOR DISEASE PROGRESSION ON RESPONSE TO ANTIRETROVIRAL THERAPY

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0529 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500
	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950

5M01RR000750-26_0529 (1998): $0

VIROLOGIC RESPONSE TO NUCLEOSIDE REGIMENS AFTER PROLONGED ZDV OR DDI MONOTHERAPY

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0530 (1999): $0

5M01RR000750-26_0530 (1998): $0

RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1999-12-01

Project end date: 2000-11-30

2M01RR000750-28_0620 (2000): $0

5M01RR000750-27_0620 (1999): $0

5M01RR000750-26_0620 (1998): $0

PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Keywords: AIDS /HIV diagnosis; blood chemistry; case history; clinical research; clinical trials; human subject; mass screening; patient /disease registry

Project start date: 1999-12-01

Project end date: 2000-11-30

2M01RR000750-28_0289 (2000): $0

5M01RR000750-27_0289 (1999): $0

5M01RR000750-26_0289 (1998): $0

RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF INDINAVIR SULFATE (IDV)

H Kenneth, Professor
Indiana Univ-purdue Univ At Indianapoliscity: Indianapolis country: United States (us)

Project start date: 1998-12-01

Project end date: 1999-11-30

Budget start date: 1-OCT-1998

Budget end date: 30-SEP-1999

5M01RR000750-27_0545 (1999): $0

Sponsored Links Excellgen http://Excellgen.com

	Baculovirus Protein Expression Fast turn around, >95% purity functional protein. No outsourcing to China or India. ~~$5500~~, $3950
	Transient Protein Expression in CHO and HEK293 Cells Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. ~~$5500~~, $3950
	Recombinant Lentivirus & Adenovirus High Yield and High Titer up to 10¹⁰ (lentivirus) and 10¹³ (adenovirus) for Guaranteed Expression of GOI. ~~$3000~~, $2500